DALLAS--(BUSINESS WIRE)--

Dallas-based internal medicine physician, Maureen Gutierrez, MD, opened her new internal medicine practice on Aug. 1 and is now seeing both new and current patients. The Dallas Comprehensive Medical Care office is located at 8220 Walnut Hill Lane, PPB II Suite 314 in Dallas. Gutierrez brings five years of experience at Harvill-Tschumy Internal Medicine Clinic to her new endeavor while remaining part of the medical staff at Texas Health Presbyterian Hospital.

I am very excited to explore an innovative side of medicine through a practice that uses modern amenities such as the Internet and social networking to connect with my patients and provide great healthcare, said Gutierrez.

Gutierrez began her medical career at the University of Virginia where she completed her pre-medical training and graduated with a Bachelor of Arts in Biochemistry in 1997. After teaching math and science in Houston, Texas, for three years, she continued her studies at the University of Texas at Houston where she received her medical degree in 2004. Gutierrez spent the next four years in specialty training and residency in internal medicine at Georgetown University Hospital in Washington, D.C., where she was appointed chief resident and served one year as an instructor to internal medicine trainees. Now she is a board certified internist through the American Board of Internal Medicine with her own private practice.

In addition to attending medical school, Gutierrez was involved with Teach for America, HISD (Houston Independent School District) and KIPP Academy. From these experiences I learned that first and foremost my job as a physician is still that of a teacher. You cannot simply tell someone what to do, you have to explain and educate, said Gutierrez. This has influenced the way I approach my patients.

Gutierrez moved to the Lone Star State in 2008 where she joined Texas Health Dallas. When shes not treating patients, the dedicated and loyal doctor is like every other mother. She enjoys spending free time with her husband and two sons, and loves a good book. She is currently training for her first half-marathon in the fall. Gutierrez has exceptional time management skills while each of her patients has her full attention, she still makes time for her family.

At the end of the day, building relationships with each of my patients is most important. I am a people pleaser so my goal is to answer every question and address every complaint while still spending the right amount of time with my family, said Gutierrez.

Her long-term goal for her practice is plain and simple - to provide great healthcare to the Dallas community. To make an appointment, call 214-865-7001 or visit http://www.dallascare.com for more information.

Read the original post:

Maureen Gutierrez, MD, Opens New Private Practice in Dallas

Four emergency medicine physicians have recently joined the Emergency Services department at Providence Medical Center, Kansas City, Kan. They include Ryan Burch, D.O.; J. Michael Donohue, Jr. M.D.; Mark J. Foland, M.D.; and Jennifer J. von Fintel, M.D.

Greg Epperson, M.D., a board-certified emergency medicine physician, serves as medical director of the hospitals recently re-designed Emergency Services department.

Other dedicated Providence Emergency Services physicians include Timothy H. Elliott, M.D., and Joshua J. Hillen, M.D.

All of the physicians are employed by EmCare, a leading provider of physician services for emergency departments throughout the United States.

All of our new physicians are dedicated to caring for patients at Providence, Dr. Epperson says. Each one is residency trained in emergency medicine, making them highly qualified to serve our community.

About the new Providence Emergency Medicine physicians:

Ryan Burch, D.O.Dr. Burch completed his residency in emergency medicine at Doctors Hospital Emergency Medicine Residency Program, Columbus, Ohio. He received his doctor of osteopathic medicine from Kirksville College of Osteopathic Medicine, Kirksville, Mo., and his bachelors degree from Truman State University, also in Kirksville.

He is a member of the American College of Emergency Physicians; the American College of Osteopathic Emergency Physicians; the American Osteopathic Association; and the Emergency Medicine Residents Association.

J. Michael Donohue, Jr., M.D.Dr. Donohue performed his residency in emergency medicine at the University of Missouri-Kansas City, Mo., Truman Medical Center. He earned his medical degree from the University of Minnesota Medical School, Minneapolis, Minn., and received his bachelors degree from St. Olaf College, Northfield, Minn.

He is a member of the American College of Emergency Physicians.

See the original post:

Four emergency medicine physicians join Providence Medical Center Emergency Services

What's inside your medicine cabinet? | Photo by trec_lit, CC. Click on image for license and information.

What story would your medicine cabinet tell about you?

Medicine cabinets are amazing spaces. They can contain a multitude of pills, pastes, syrups, and wrappings that we know we can reach for to manage many types of pain, ailments, and illnesses ourselves. They can provide a window into a persons well-beingreally? youve never peeked after washing your hands?and tell us what works for them. Such forays can give us a basis for making decisions about similar conditions. After all, medicine cabinets house a collection of expertiseall packaged in a way to make them identifiable and trustworthy so that in the absence of a physician, were confident of receiving treatment within the promised parameters of healing.

Between 24-hour pharmacies (1) and Web MD, at any given moment we have access to patented non-prescription, or over-the-counter (OTC), medications, and medical information that we are free to weigh and use at our own discretion. We might take this for granted as we reach for that bottle of antacids or pain relievers or cough syrup, but the establishment of non-prescription patented medication represents a significant movement toward access to standardized health remedies. And as discussions about access to health care rage around us in the United States, OTC medication has become for many a primary means of treating ailments. The standard of care in our medicine cabinets is increasingly for many a measure of health

Packaging a Cure

In the video game Assassins Creed when youre in need of medical attention you have the option of visiting a medical stand and purchasing medicine vials meant to completely cure your ailments, whatever they might be. While no such miracle cure really exists, the medical experience in the game isnt all that far from the reality of health care for much of history. While medical professionals were required to have training, the standard of practice variedparticularly in the 17th-, 18th-, and early 19th-centuries when medical care was dispensed by physicians, doctors, barber-surgeons, and apothecaries.

The advent of the Scientific Revolution and the following Age of Enlightenment saw an explosion of cross pollination between the sciences that allowed doctors to treat illnesses and injuries with greater success. However, during this period and up to the early 19th-century, the odds of a single patient receiving successful treatment from a physician were 50-50 (2). Methods of treatments varied in accordance to superstition, astrology, and religion. For example, the doctrine of signatures maintained that God had provided a natural cure for every illnessas was evidenced by the resemblance some herbs bear to various parts of the body (i.e., liverwort could cure ailments relating to the liver). And ideas about balance were rampant; the prevalence of the theory of humoursthat there were four fluids in the body (black bile, yellow bile, phlegm, and blood) that needed to be in balance for good healthencouraged the practice of bloodletting.

In this context, physicians sought to distinguish themselves by patenting their cures, which meant serving them in specific bottles and with particular labels. The more famous of these include Godfreys Cordial, Dalbys Carminative, Batemans Drops, Turlingtons Balsam of Life, Steers Opodeldoc, British Oil, Daffys Elixir, and Balsam of Honey (2). But patents werent enough to cement these cures as trustworthy in the minds of the purchasing public. But the longstanding success of these medications was also in part due to their reproducibility. They were easily counterfeited, right down to their packagingbut they were chosen to be counterfeited because they worked. So in a sense, they became public property. You wouldnt be too far off in thinking of these early counterfeits as generic brand medications. The public trust in the formulas allowed drove the market for patented (and counterfeited) cures in more rural areas where obtaining medical care was a challenge. These formulas in their tell-tale bottles and wrappings placed medical treatment conveniently within reach of many people.

The Essence of Peppermint: A Case Study

The Essence of Peppermint [pdf] provides a useful case study in considering the factors of success, trust, and counterfeiting in creating a standard of care via patented medication.

Read the original:

Standards of Healthcare in Your Medicine Cabinet

Newswise Dr. Mark Cichon, DO, has been named chair of the new Department of Emergency Medicine of Loyola University Medical Center.

Cichon formerly was head of the division of Emergency Medicine within the Department of Surgery at Loyola. As of July 1, the division is elevated to department status.

As a full, stand-alone department, the new Department of Emergency Medicine will be better positioned to enhance academic needs for both students and faculty and allow for richer academic growth, faculty development, faculty recruitment and retention. This change aligns with national trends over the past decade, as an increasing number of emergency medicine divisions have become full departments.

Cichon has served as division director for Loyola Emergency Medicine for the past 16 years. Dr. Cichon has shown that he more than meets the academic needs of both students and faculty, said Dr. Richard Gamelli, MD, FACS, senior vice president and provost, Health Sciences, Loyola University Chicago. He also has demonstrated how emergency medicine physicians serve the didactic needs of students as well as serving the continued growth of the faculty within the department.

Since 1995, annual patient volumes in Loyolas emergency division have increased from 29,000 to 53,000 patients. The Loyola emergency department is for many patients a portal of entry to Loyola University Health System for complex care, said Dr. Gamelli, who also serves as Director, Burn & Shock Trauma Institute and Chief, Burn Center at Loyola. The division also has instituted several programs to improve care for critically ill patients, including the Heart Attack Rapid Response Team, Stroke Program, Sepsis Program and Hypothermia Program.

The Loyola emergency medicine division is classified as a Level 1 Trauma Center, providing the highest level of surgical care to trauma patients. The division also has been recognized by groups such as The Joint Commission, the Commission on Accreditation of Medical Transport Systems, the American College of Surgeons for Trauma and the Illinois Department of Public Health for Trauma, Burns, Pediatric and Emergency departments.

Continue reading here:

Dr. Mark Cichon Named Chair of Loyola Department of Emergency Medicine

SIPO of China has recently approved an alternative herbal treatment for endometrial hyperplasia and adenomyosis. Bringing no side effect, the herbal medicine completely treats endometrial disorders, which solves fertility problems for sufferers.Wuhan, Hubei Province (PRWEB) August 10, 2012 A new patented herbal medicine Fuyan Pill offers relief of two endometrial disorders: endometrial ...

Read more from the original source:

Herbal Medicine Offers Relief of Endometrial Hyperplasia and Adenomyosis, Says Dr. Lee Xiaoping from China

Published: Aug. 10, 2012 at 12:07 PM

MEDICINE HAT, Alberta, Aug. 10 (UPI) -- Tattoo advocates are decrying a policy imposed on police officers in an Alberta town requiring them not to have any visible tattoos or piercings.

Medicine Hat Police Chief Andy McGrogan said policy, which was put in place after a Medicine Hat police officer asked for permission to display a tattoo while on duty, is based on the results of a 2011 survey in the town that indicated residents prefer police officers not to display tattoos, piercings or unnaturally colored hair, the Canadian Broadcasting Corp. reported Friday.

"It's not what I think, it's what members of the community think," McGrogan said. "At the end of the day, our community has spoken and we just changed our policy to reflect that."

Samantha Barron, who owns a Medicine Hat tattoo shop, said she does not agree with the policy.

"I think it's pathetic that the police officers with tattoos now have to hide who they are," she said. "And it makes them less a part of our community."

McGrogan said the policy may be revisited in the future.

See the rest here:

Canadian police ban tattoos, piercings

A new policy banning visible tattoos and piercings for police officers is creating a stir in Medicine Hat, Alta.

Chief Andy McGrogan says he's pleased with the changes, which prohibit his officers from revealing any tattoos, piercings or wearing unnaturally coloured hair.

The changes are well researched thanks to a 2011 community survey that showed residents favoured appearance standards for police, McGrogan said.

Its not what I think, its what members of the community think, McGrogan told CBC News. At the end of the day, our community has spoken and we just changed our policy to reflect that.

McGrogan says the force already has a policy that requires members to cover tattoos, but this new rule ups the restrictions placed on officers.

The biggest change will be for women who wear earrings any piercings around the face, including ears, have been determined to be unsafe.

The policy change stemmed from a tattooed officer requesting to display his tattoos.

Staff Sgt. Brent Secondiak said staff were not surprised by the new policy.

I would say most of the members probably have a small one at one place or another. Very few have sleeves or exposed tattoos on their arms, Secondiak said. Were OK with it. Were really here to serve the community.

In Ontario, the provincial police attempted to place restrictions on tattoos, but that decision was later overturned.

Excerpt from:

Medicine Hat police must hide tattoos, piercings

BG Medicine Inc. reported a wider net loss in the second quarter of $6.4 million the Waltham company cited higher costs and it withdrew an application to the Food and Drug Administration for approval for a diagnostic test. The company said it could not meet an Aug. 15 FDA deadline to supply more information about its CardioScore test but plans to resubmit the application for regulatory approval. CardioScore is its lead product candidate a blood test for atherothrombotic cardiovascular disease, commonly known as vulnerable plaque.

For more from BostonGlobe.com, sign up or log in below

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Unlimited Access to BostonGlobe.com for 4 weeks for only 99.

Get FREE access as part of your print subscription.

See the rest here:

BG Medicine’s net loss widens

Navy Capt. Gail L. Hathaway, the deputy commandant of the Medical Education and Training Campus, based at Joint Base San Antonio-Fort Sam Houston, assumed command of the newly reorganized Navy Medicine Education and Training Command from Rear Adm. Eleanor Valentin July 11 in Jacksonville, Fla.

Rear Adm. Michael H. Mittelman, deputy surgeon general of the Navy and deputy chief of U.S. Navy Bureau of Medicine and Surgery, served as the presiding officer. Hathaway will command from the new NMETC headquarters located at Building 1001 on JBSA-FSH. Valentin will become director for implementation, Defense Health Agency, reporting to the Assistant Secretary of Defense for Health Affairs.

The Navy Medicine Support Command, commissioned Nov. 1, 2005, was renamed NMETC during the ceremony, with the former NMSC's responsibilities re-focused primarily on Navy medicine's education and training mission.

The realignment of NMSC stems from the Navy surgeon general's vision of streamlining Navy medicine into a more effective, efficient and responsive organization that improves accountability, and command and control.

A vanguard unit of 12 military and civilian personnel will man NMETC's new headquarters location with approximately 65 personnel remaining at the Jacksonville, Fla., and Bethesda, Md., locations as planning continues on specifics for NMETC's future consolidation.

NMETC is part of the Navy Medicine enterprise, a global health care network of 63,000 Navy medical personnel around the world who provide high-quality health care to more than one million eligible beneficiaries.

Navy Medicine personnel deploy with sailors and Marines worldwide, providing critical mission support aboard ship, in the air, under the sea and on the battlefield.

Larry Coffey is a writer with the Navy Medical Education and Training Campus public affairs office at Joint Base San Antonio-Fort Sam Houston.

Here is the original post:

METC deputy heads Navy Medicine Education and Training Command

WALTHAM, Mass., Aug. 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) today announced its consolidated results of operations for the three and six months ended June 30, 2012 and provided a business update. The Company will host a conference call and webcast today, August 9, 2012, beginning at 8:30 a.m. Eastern Time (details follow below).

For the quarter ended June 30, 2012, the Company reported a consolidated net loss of $6.4 million compared to a consolidated net loss of $4.8 million for the quarter ended June 30, 2011. For the six months ended June 30, 2012, the Company reported a consolidated net loss of $14.1 million compared to a consolidated net loss of $8.0 million for the six months ended June 30, 2011.

At June 30, 2012, the Company had consolidated cash, cash equivalents and marketable securities totaling approximately $23.3 million.

Business Update

"We are very pleased with the significant progress we have made during the past several months," said Eric Bouvier, president and CEO of BG Medicine. "We continue to invest in the franchise for the BGM Galectin-3(R) test, and we have had a number of recent positive developments related to our galectin-3 program. In July 2012, we announced the filing of a 510(k) for regulatory clearance for the ARCHITECT(R) galectin-3 assay, which is used with Abbott's fully automated ARCHITECT(R) immunochemistry instrument platform. This important milestone represents the first filing of an automated platform version of the BGM Galectin-3 test from our strong group of four automated platform partners, Abbott, Alere, bioMerieux, and Siemens. In May 2012, we filed a 510(k) to extend the cleared labeling indication for the BGM Galectin-3 test to include individuals in the general adult population who are at risk for developing heart failure based on elevated levels of galectin-3. We obtained CE Mark in the European Union for this expanded indication for the BGM Galectin-3 test and we are working with our partners to begin commercialization. Finally, in June 2012, we announced that Atherotech Diagnostic Lab is now making galectin-3 testing available to its laboratory customers and physicians.

"We have been continuing our dialogue with the FDA regarding the 510(k) submission for our CardioSCORE TM test," continued Mr. Bouvier. "The FDA has requested that we conduct an adjudication process to confirm certain data from our BioImage validation study. The data were originally obtained through medical insurance claims, a method previously validated in numerous peer-reviewed studies. Due to the time involved in the adjudication process, we determined that we would not be able to submit a complete response by the August 15, 2012 deadline. Therefore, we withdrew the 510(k) on August 8, 2012. We intend to submit a new 510(k) as soon as we are satisfied that the information requested by the FDA is addressed in the new submission. We remain very confident about the performance of the CardioSCORE test, and the submission of a thorough and responsive 510(k) is one of our highest priorities.

"We are looking forward to several important milestones for the Company over the next several months," concluded Mr. Bouvier. "We will continue to focus on the achievement of these milestones to make our innovative products a success in the marketplace."

Upcoming milestones include:

Financial Results

Three months ended June 30, 2012

Excerpt from:

BG Medicine Announces Fiscal 2012 Second Quarter Results

Harry Potter's World: Renaissance Science, Magic and Medicine - a traveling exhibition from the National Library of Medicine that explores the Harry Potter book series' roots in the Renaissance traditions which played an important role in the development of Wester science and medicine - is on display now through September 10.

Read this article:

Harry Potter Medicine exhibit

Conference on Chinese Herbal Medicine Among Highlights

Hong Kong, Aug 8, 2012 - (ACN Newswire) - More than 110 exhibitors and a score of expert speakers will present the latest Chinese medicine products, services and intelligence at the 11th edition of the International Conference & Exhibition of the Modernization of Chinese Medicine & Health Products (ICMCM), which will take place, 16-18 August, at the Hong Kong Convention and Exhibition Centre.

Jointly organised by the Hong Kong Trade Development Council (HKTDC) and the Modernized Chinese Medicine International Association, the event will be dedicated to trade visitors over the first two days before welcoming the public on 18 August.

"In view of the growing health consciousness around the world and the increasing demand for health products and services, ICMCM continues as a fair and conference to provide a one-stop trading, shopping and information exchange for Chinese medicine and health products," said Modernized Chinese Medicine International Association President Vivien Chou, speaking at today's press conference. "Recognised as one of the world's leading events of its kind, ICMCM will provide insights into the development of Chinese medicine and health products."

Exhibitors and Themes

The fair will feature exhibitors from Canada, Hong Kong, Japan, Korea, Macau, Singapore, Taiwan and the Chinese mainland, with three provinces Guizhou, Jilin and Qinghai organising group pavilions.

The exhibition will be divided into the following theme zones: Chinese Medicine, Health Supplements, Healthcare & Therapy, Raw Material, Equipment & Related Services, and Research & Development.

Conference Highlights

A two-day conference under the theme "Chinese Herbal Medicine for Major Disease Burden and Health Promotion," will discuss the latest findings and applications of Chinese medicine. Topics will include preventive treatment of disease, Chinese herbal medicine for vascular and immunological diseases and the bioactivity and standards of Chinese herbal medicine.

Speakers will come from the mainland, Hong Kong, Japan, Macau, the Netherlands, Singapore, Taiwan and the United States. They will include Professor Li Da-ning, Vice Commissioner of the mainland's State Administration of Traditional Chinese Medicine, Professor Chen Kai-xian, Presidentof Shanghai University of Traditional Chinese Medicine, Professor Zhang Bo-li, President of Tianjin University of Traditional Chinese Medicine, and Dr David Eisenberg, Associate Professor of Medicine and Public Health at Harvard University. Dr Mei Wang, Director of the Netherlands' SU BioMedicine, will speak on the first successful registration of a Chinese herbal medicine in the European Union.

Read the original:

Chinese Medicine Fair to Spotlight Health Solutions

MEDICINE PARK, Okla_It has been a little over a year since fires tore through Medicine Park threatening many homes and burning thousands of acres. We wanted to go back and check on those who live in Big Rock Estates to see how things look one year later, and find out how things might have changed since the fires.

The Fahrion family has lived in Big Rock Estates for 10 years. They say when the fire first broke out, they were terrified, fearing that their home they had worked so hard to put together would go up in flames. They were one of the luckier families. Their home was still standing after the fire came through, but the siding was charred, and the inside was covered in soot. A year later they say they are happy with the rebuilding progress and glad to still call Medicine Park home.

Muriel Fahrion said she will never forget hearing the dreadful knocking at her door with firefighters telling her to evacuate her home because fires would soon be taking over Medicine Park.

"It was extremely scary. What do you grab if you have to evacuate?"

Ten minutes later, Muriel said they grabbed what they could and ran outside. In that short amount of time, ash had begun falling on their heads. She said that's when it became real.

For the next few days Muriel and her husband kept a close eye on the fire. When they were able to return, they saw their home standing but not the way they had left it.

"The outside we had maybe 2/5 of the house was the cedar siding, all that cedar siding because fire surrounded the house it came from all sides all curled and it was worthless."

Now the once cedar siding wall is hardy board, a molded concrete mix not to mention the inside of the house had to be repainted and completely washed down. Soot covered the inside of the home and trees that once stood lush were now burnt to a crisp.

"It was so much more than I think people even think is going to happen. With a fire they hear on TV their house was saved but meanwhile a month later and $33,000 we were finally back to at least being able to live in our house."

Muriel said no amount of fire damage would keep them out of Medicine Park. She said she's thankful that though the fire tried to take down the house it didn't bring down their determination to get their home back where it once was.

View post:

Medicine Park family recovered after 2011 fires

Puentes de Salud co-founders Steve Larson, MD, associate professor, Emergency Medicine, and Matthew O'Brien MD, MSc, were recently selected for an Emerging Leaders Fund grant from the Claneil Foundation to support Puentes de Salud, a nonprofit free health clinic for Latino immigrants in Philadelphia.

The Emerging Leaders Fund provides founders and leaders of young organizations who show great potential for strong positive impact with $200,000 of unrestricted funding over four years and a peer group of other leaders for guidance. The organization turns to more than 80 sources to pool prospective recipients and then selects up to four annually.

Puentes de Salud was founded on the belief that community health and wellness are not the domain of merely one group or discipline, but rather a collaborative community effort. The organization partners with community leaders, local government, educational, and nonprofit institutions to address the detrimental economic and social attributes impacting the health of South Philadelphia's Latino population. In doing so, Puentes de Salud promotes health and wellness in this population and educates future generations of community advocates, health care providers, educators and leaders by offering opportunities for responsible and respectful community engagement.

"It is a tremendous honor for Puentes de Salud to receive this award from the Claneil Foundation and acknowledges the passion, patience, and perseverance that has defined the dedicated efforts of countless Puentes volunteers to ensure the health and wellness of South Philadelphia's vibrant, yet vulnerable Latino immigrant population," said Larson.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Excerpt from:

Penn Medicine Professor Selected for Emerging Leaders Fund Grant from the Claneil Foundation to Support Puentes de Salud

Public release date: 7-Aug-2012 [ | E-mail | Share ]

Contact: Lorinda Klein lorindaann.klein@nyumc.org 212-404-3533 NYU Langone Medical Center / New York University School of Medicine

New York (August 7, 2012) A new clinical trial designed to study how worm eggs may relieve symptoms of ulcerative colitis (UC) will begin enrolling patients at NYU School of Medicine's Clinical and Translational Science Institute. This unusual therapy has been used in previous clinical trials on patients with inflammatory bowel diseases, but the mechanism of action is unclear.

"The goal of this study is to understand the mechanisms that may explain why worm eggs can improve the symptoms of UC." says the study's Principal Investigator, P'ng Loke, PhD, assistant professor of microbiology. "Understanding these mechanisms may lead to new treatment strategies and also help identify people that are most likely to respond to treatment with worm eggs."

UC is a chronic disease that is characterized by open sores or ulcers in the lining of the colon. According to the Crohn's and Colitis Foundation of America, the disease is estimated to affect 700,000 Americans. Symptoms include abdominal pain and bloody diarrhea. While the cause is unknown, studies suggest that a defective response against commensal (normal microflora) gut bacteria could be responsible.

Colitis is common in North America and Northern Europe, where helminth (parasitic worm) infections are rare. Conversely, the disease is rare in Asia, Africa, and Latin America, where helminth infections are endemic, leading researchers to hypothesize that the worms offer protection against this inflammatory bowel disease. In animal models of autoimmunity these worms have suppressed inflammation, and clinical trials indicate that helminth therapy can be beneficial in relieving symptoms of inflammatory bowel diseases.

In 2005, Dr. Joel Weinstock and colleagues at the University of Iowa published a series of human studies showing that eggs from the pig whipworm Trichuris suis (TSO) had positive effects in both Crohn's disease as well as ulcerative colitis patients, which are two different types of inflammatory bowel diseases. Several large studies on TSO are underway for a number of different immune disorders.

In 2010, Dr. Loke and his colleagues reported a detailed study of a man with UC who ingested Trichuris trichiura eggs to relieve his own symptoms. Based on the samples that were analyzed from this man, the researchers hypothesized that the immune response activated to expel the parasites through increased cell turnover in the intestinal lining and increased mucus production may have improved his symptoms. They followed up these observations with a study on monkeys that showed that this response also changed the type of bacteria and reduced the amount of bacteria attached to the intestinal lining.

"We think that by altering the lining of the intestine, the worms may change the quantity and type of bacteria that are attached to the intestinal wall." says Dr. Loke. "We are now ready to test this idea in a human clinical trial."

###

Read more from the original source:

NYU School of Medicine announces new clinical trial for ulcerative colitis

NEW YORK, Aug. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0943293/Japanese-Market-for-Orthopedic-Soft-Tissue-Repair--Sports-Medicine.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

The Japanese market for orthopedic soft tissue repair and sports medicine exceeded

$1 billion in 2011.

The orthopedic soft tissue repair and sports medicine market includes shoulder repair(rotator cuff and shoulder labrum repair), knee repair (anterior and posterior cruciateligament fixation products and meniscal repair devices) and hyaluronic acidviscosupplementation. None of these segments were affected by the financial crisis in 2011;instead, the market was more hindered by the Great East Japan Earthquake and appreciationof the Japanese yen. Nonetheless, there was a spike in growth in 2011 due to the introductionof a three-injection cycle hyaluronic acid viscosupplementation product in late 2010

This report includes information about:

Japanese Shoulder Repair MarketJapanese Knee Repair MarketJapanese Hyaluronic Acid Viscosupplementation Market

This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2018, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.

EXECUTIVE SUMMARY . 11.1 JAPANESE MARKET FOR ORTHOPEDIC SOFT TISSUE REPAIR & SPORTS MEDICINE..... 11.2 SHOULDER REPAIR PROCEDURES .... 21.3 ACL/PCL FIXATION DEVICE MARKET ... 31.4MENISCAL REPAIR MARKET ..... 41.5 HYALURONIC ACID VISCOSUPPLEMENTATION MARKET ... 51.6 COMPETITIVE ANALYSIS ... 6RESEARCH METHODOLOGY ..... 72.1 RESEARCH SCOPE 72.2 IDATA'S 9-STEP METHODOLOGY .... 7Step 1: Project Initiation & Team Selection ..... 8Step 2: Prepare Data Systems and Perform Secondary Research ..... 10Step 3: Preparation for Interviews & Questionnaire Design ..... 11Step 4: Performing Primary Research ..... 12Step 5: Research Analysis: Establishing Baseline Estimates ..... 14Step 6: Market Forecast and Analysis ..... 15Step 7: Identify Strategic Opportunities .. 17Step 8: Final Review and Market Release ...... 18Step 9: Customer Feedback and Market Monitoring .... 19JAPANESE SOFT TISSUE REPAIR & SPORTS MEDICINE MARKETOVERVIEW . 203.1 INTRODUCTION .. 203.1.1 Shoulder Soft Tissue Repair ..... 203.1.2 Knee Soft Tissue Repair .... 213.1.3 Hyaluronic Acid Viscosupplementation . 213.2 CURRENCY EXCHANGE RATE . 223.3MARKET OVERVIEW . 233.4 TREND ANALYSIS ..... 283.5MARKET DRIVERS AND LIMITERS . 313.5.1 Market Drivers .... 313.5.2 Market Limiters ... 333.6 COMPETITIVE ANALYSIS . 343.6.1 Leading Competitors .. 343.7MERGERS AND ACQUISITIONS 41JAPANESE SHOULDER REPAIR MARKET . 424.1 INTRODUCTION .. 424.1.1 Rotator Cuff Repair ... 424.1.2 Shoulder Labrum Repair .. 444.2 PROCEDURES ...... 454.3MARKET OVERVIEW . 464.4MARKET ANALYSIS & FORECAST . 514.5MARKET DRIVERS AND LIMITERS . 604.5.1 Market Drivers .... 604.5.2 Market Limiters ... 604.6 COMPETITIVE ANALYSIS . 62JAPANESE KNEE REPAIR MARKET ..... 665.1 INTRODUCTION .. 665.1.1 ACL/PCL Repair . 665.1.2 Meniscal Repair .. 675.2 PROCEDURES ...... 685.3MARKET OVERVIEW . 695.4MARKET ANALYSIS & FORECAST . 745.4.1 ACL/PCL Repair Market .. 745.4.1.1 Tibial Fixation Market by Segment .....795.4.1.2 Femoral Fixation Market ......885.4.2 Meniscal Repair Market by Segment ..... 975.5MARKET DRIVERS AND LIMITERS ...... 1065.5.1 Market Drivers .. 1065.5.2 Market Limiters . 1075.6 COMPETITIVE ANALYSIS ...... 108JAPANESE HYALURONIC ACID VISCOSUPPLEMENTATION MARKET . 1146.1 INTRODUCTION 1146.1.1.1 Single-Injection Products ....1156.1.1.2 Three-Injection Cycle Products ..1156.1.1.3 Five-Injection Cycle Products ....1156.2MARKET ANALYSIS & FORECAST ...... 1166.3MARKET DRIVERS AND LIMITERS ...... 1236.3.1 Market Drivers .. 1236.3.2 Market Limiters . 1246.4 COMPETITIVE ANALYSIS ...... 125ABBREVIATIONS ... 128

MoreMarket Research Report

Originally posted here:

Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine

Foundation Medicine Inc. and Clovis Oncology Inc. said today they will work together to develop an in-vitro test for identifying biomarkers in specific cancer patients who would most likely respond to a Clovis drug.

The companies said they will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an in-vitro diagnostic method to identify patients, including those with ovarian cancer, with tumors most likely to respond to the drug rucaparib.

Foundation Medicine is a Cambridge-based molecular information company. Clovis, a biopharmaceutical company, is based in Boulder, Colo.

Foundation Medicines core capability is the translation of genomic insights into clinically actionable information, said company president and CEO Michael Pellini. But even the most in-depth genomic profile for a patient is only as actionable as the available and relevant targeted therapies. Therefore, we are working to help expand the universe of targeted therapeutic options. Clovis Oncology, a recognized leader in patient specific oncology drug development, is an ideal partner in this mission.

Read the original here:

Cambridge's Foundation Medicine launches drug collaboration

A medicine ball is a weighted ball that comes in a variety of weights. It is a very inexpensive piece of equipment that is easy to store and can be used for a wide variety of exercises.

Read the original here:

Hot 'n' Healthy: Tone up with medicine ball push-ups and leg raises

NEW YORK, Aug. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Indian Market for Orthopedic Soft Tissue Repair & Sports Medicine

http://www.reportlinker.com/p0943294/Indian-Market-for-Orthopedic-Soft-Tissue-Repair--Sports-Medicine.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

The Indian market for orthopedic soft tissue repair and sports medicine exceeded $17 million in 2011.

The orthopedic soft tissue repair and sports medicine market includes shoulder repair (rotator cuff and shoulder labrum repair), knee repair (anterior and posterior cruciate ligament fixation products and meniscal repair devices) and hyaluronic acid viscosupplementation. The market was not affected by the financial crisis in 2011 and will continue growing rapidly with the rise in sports medicine surgeons and awareness of the sports medicine field.

This report includes information about:

Indian Shoulder Repair Market

Indian Knee Repair Market

Indian Hyaluronic Acid Viscosupplementation Market

This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2018, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.

Read more:

Indian Market for Orthopedic Soft Tissue Repair & Sports Medicine

CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--

Foundation Medicine, Inc. and Clovis Oncology, Inc. (CLVS) announced today that they have entered into a diagnostic collaboration. The goal of the collaboration is to develop an in-vitro diagnostic (IVD) to identify biomarkers to select cancer patients most likely to respond to Clovis product candidate rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor currently in Phase I/II clinical development.

We are pleased to collaborate with Foundation Medicine, said Patrick J. Mahaffy, president and CEO of Clovis Oncology. This continues our commitment to developing targeted therapies with companion diagnostics to identify the patients most likely to benefit from our therapeutics. Foundation Medicines leadership in next generation sequencing and genomic analysis make them an ideal partner to work with us on our rucaparib program.

Foundation Medicine and Clovis Oncology will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an IVD method to identify patients who have tumors more likely to respond to rucaparib.

In particular, the goal of the collaboration is to identify the additional genetic mutations beyond those in germ-line and somatic BRCA that are associated with defective DNA repair and may define appropriate tumor targets for rucaparib. In high-grade serous ovarian cancer, for example, this study has the potential to increase the percentage of ovarian cancer patients potentially eligible for rucaparib therapy from the 15 percent typically found to have germ-line mutations of BRCA to an estimated 40 to 50 percent who have DNA repair deficiencies caused by somatic mutations in a variety of genes.

Foundation Medicines core capability is the translation of genomic insights into clinically actionable information, said Michael J. Pellini, M.D., president and CEO of Foundation Medicine. But even the most in-depth genomic profile for a patient is only as actionable as the available and relevant targeted therapies. Therefore, we are working to help expand the universe of targeted therapeutic options. Clovis Oncology, a recognized leader in patient-specific oncology drug development, is an ideal partner in this mission.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical product, FoundationOne, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.foundationmedicine.com.

Continued here:

Foundation Medicine and Clovis Oncology Announce Diagnostic Collaboration